ZD1839 (Iressa™) and concurrent chemo-radiation in patients with locally advanced non small cell lung cancer
Study identifier:D7913C00073
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I Trial to evaluate ZD1839(Iressa™) and concurrent chemo-radiation in patients with locally advanced non small cell lung cancer
Medical condition
Non Small Cell Lung Carcinoma
Phase
Phase 1
Healthy volunteers
No
Study drug
Gefitinib, Carboplatin, Paclitaxel
Sex
All
Actual Enrollment
44
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jul 2002
Primary Completion Date: -
Study Completion Date: 01 Oct 2005
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Australia Medical Director
AstraZeneca
